COVID-19: CARB-X remains open for business – virtually
CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.
Even as we cope with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.
CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $222.06 million in 61 projects around the world.
focused on new classes
“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”
— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.